There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy characterized
by hemolysis, platelet consumption, and renal injury. Eculizumab, a mAb that blocks
complement activity, has been successfully used in aHUS.